Partner Darren Smyth has had an article on the Seroquel case published on the website of the Controlled Release Society.
The regular ‘Inside Track’ feature provides insider knowledge on recent developments in the science and technology of controlled release.
Darren’s article outlines the background to a case involving AstraZeneca's patent for the sustained release formulation of quetiapine, marketed under the brand name Seroquel. He looks at the reasons for two differing judgements and implications for IP strategy to protect sustained release products.